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ABSTRACT
	
  
Tobacco use remains the leading cause of preventable disease and death in the United
States. Despite increased research and improved treatment modalities, rates of lapse and relapse
remain high. Women in particular experience poorer smoking cessation outcomes (including
more relapse), presumably due to unique considerations such as the hormonal milieu. Despite
some conflicting results, researchers have speculated that timing cessation attempts to coincide
with the luteal phase of the menstrual cycle, where levels of neuroprotective progesterone are at
their peak, may decrease nicotine withdrawal and increase cessation success. Timing treatment
onset with the luteal phase may positively impact smoking variables that influence cessation,
such as withdrawal symptoms, tobacco craving, self-efficacy to quit, and motivation to quit
among female smokers. The current study investigated if the luteal phase results in lower selfreported severity of withdrawal symptoms and tobacco cravings, as well as higher reported selfefficacy and motivation to quit, compared to study participants in the late follicular phase.
Female participants (n = 9; luteal phase n = 5, late follicular phase n = 4) completed online study
measures. Menstrual cycle phase was determined based upon self-report (i.e., length of menses,
length of cycle, last previous menses, next expected menses). Participants in the luteal and late
follicular phases did not differ in smoking cessation-related variables (i.e., withdrawal severity,
craving intensity, self-efficacy, motivation). Additionally, there was no evidence that the
smoking cessation-related variables moderated the relationship between phase group and
motivation to quit.
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INTRODUCTION
Tobacco use is the leading cause of preventable death and disease in the United States.

In 2010, the Surgeon General reported that more than 440,000 people die annually from
smoking-related deaths (Centers for Disease Control and Prevention [CDC], 2012; United States
Department of Health & Human Services [USDHHS], 2010). Tobacco use has been linked to a
variety of medical conditions such as chronic bronchitis, emphysema, stroke, myocardial
infarction, hypertension, and coronary heart disease. Smoking accounts for approximately onethird of all cancers and 90% of lung cancer (USDHHS, 2010). However, despite these health
risks, approximately 46.6 million people in the United States over the age of 18 currently smoke
cigarettes. Approximately 16.5% of all females in the United States smoke (Agaku, King, &
Dube, 2012). Notably, females report longer durations of use compared to men. For example,
the median cessation age for females is 37 years old compared to 33 years old for males (CDC,
2012; Cepeda-Benito, Reynoso, & Erath, 2004; Pierce & Gilpin, 1996).
Among current smokers, 68.8% report a desire to quit and millions attempt to quit every
day; of those that do attempt to quit, only 3-5% maintain abstinence over 6-12 months (CDC,
2013; Hughes, Kelly & Naude, 2004). There are no consistent gender differences in the rates of
smoking cessation or motivation to quit smoking (USDHHS, 2001). However, female smokers
are particularly vulnerable to relapse (USDHHS, 2001). Across interventions, including
pharmacotherapy (such as nicotine replacement therapy [NRT]) and psychotherapy techniques,
women report lower abstinence rates and more severe withdrawal symptoms than men (Perkins,
2001; Pomerleau & Pomerleau, 1996). Data have indicated that levels of sex hormones
associated with menstrual cycle phase at quit date may affect cessation outcomes, as well as
nicotine craving, withdrawal, and relapse (Carpenter, Upadhyaya, LaRowe, Saladin, & Brady,
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2006; Lynch & Sofuoglu, 2010; McVay & Copeland, 2011; Mello, 2010). That women have
lower abstinence rates as compared to their male counterparts may be due to more distressing
levels of withdrawal, which may fluctuate across the menstrual cycle. Thus addressing female
factors related to smoking cessation attempts (e.g., withdrawal) may inform interventions
designed to decrease the incidence of relapse among female smokers.
Menstrual Cycle Phase
	
  
The female menstrual cycle (or female sexual cycle) is a monthly rhythmic pattern
characterized by changes in rates of female hormones and the releasing of an ovum (egg) for
fertilization (Guyton & Hall, 2000). This process begins during puberty. The first cycle occurs
at approximately 12 years of age. Puberty is marked hormonally by the increased production and
release of gonadotropin releasing hormone (GNRH) by the hypothalamus, which leads to the
secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) by the pituitary
gland. These pituitary hormones are responsible for follicular development and ovulation. The
secretion of FSH and LH results in an increased ovarian secretion of estrogen. Elevated estrogen
levels result in ovulation and the subsequent production of progesterone, marking menarche—the
female’s first menses (Guyton & Hall, 2000). Following irregular menses for the first 12-18
months, a female’s average menstrual cycle lasts approximately 28 days, although 25-35 days is
considered normal. Menstruation will temporarily cease during pregnancy (Jensvold, 1996;
Sherwin, 1996). In some individuals, the cycle may range anywhere between 20-45 days;
however, abnormal cycle length is often associated with decreased fertility (Guyton & Hall,
2000).
The conventional menstrual cycle is divided into the follicular (including menses and late
follicular phases) and luteal phases, which are separated by a periovulatory phase, marked by a
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mid-cycle LH surge (i.e., a rapid rise in LH), resulting in ovulation. The standardized 28-day
menstrual cycle begins with the start of menses (days 1-4) and continues into the late follicular
phase (days 5-11). During menses, both estrogen and progesterone levels are low until the
beginning of the late follicular phase. Then estrogen levels begin to elevate, while progesterone
levels remain low (Davidsen, Vistisen, & Astrup, 2007). The estrogen levels peak during the
periovulatory phase (days 12-15), when ovulation occurs; these levels remain relatively elevated
throughout the luteal phase (days 16-28; Hall, 2009; Davidsen et al., 2007). Conversely,
progesterone levels continue to remain low during the periovulatory phase and do not peak until
the luteal phase (Davidsen et al., 2007). If fertilization does not occur, estrogen and
progesterone levels fall, marking the beginning of the next cycle (Guyton & Hall, 2000).
The length of the follicular phase can often fluctuate. These fluctuations are frequently
identified as the cause of individual variability in overall cycle length, varying from 4 to 19 days
(Hall, 2009). The late follicular phase is characterized by rising levels of estrogen, resulting in
the growth of the lining of the uterus (Guyton & Hall, 2000; Hall, 2009; see Figure 1). Contrary
to the late follicular phase, the length of the luteal phase remains fairly constant between cycles
and typically lasts for 10 to 16 days (Jensvold, 1996). Also, combined hormonal contraceptives
(i.e., oral, injectable, or implanted) typically inhibit this ovulation through various mechanisms
of action; these differ from “low dose” progestin oral contraceptives that act locally on the
cervix, uterus, or fallopian tubes (Jensvold, 1996b).
The monthly cycle will continue until menopause at age 51, on average (Jensvold, 1996).
Menopause is a result of depletion of ovarian primordial follicles eventually leading to
insufficient estrogen available to regulate cycling (Jensvold, 1996; Sherwin, 1996). According
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to the World Health Organization (WHO), menopause occurs gradually over a 10-year period,
and thus the process begins sometime after a female turns 40 years of age (Jensvold, 1996).

Figure 1. A representation of the typical 28-day menstrual cycle. FSH = follicular stimulating
hormone. LH = luteinizing hormone. From “Food Cravings and Food Cue Responding Across
the Menstrual Cycle,” (doctoral dissertation) by M. A. McVay, 2012, retrieved from
http://etd.lsu.edu/cgi-bin/ETD-browse/browse.
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Menstrual Cycle Phase and Smoking Cessation-Related Factors
	
  
It is well established by empirical research that female smokers experience unique
challenges when attempting smoking cessation, due to a variety of influences such as negative
affect, concerns about weight gain, available social support, and the hormonal milieu (Perkins,
2001; Mello, 2010). Although the mechanisms of these differences in smoking cessation are not
fully understood, recent research has established that the ovarian hormones (estrogen and
progesterone) may modulate nicotine withdrawal, craving, and relapse.
In a recent review, Lynch and Sofuoglu (2010) explain that progesterone may have
therapeutic utility in female smoking cessation, whereas estrogen may augment vulnerability to
cessation relapse. Progesterone acts as a neuroprotective substance through numerous short- and
long-term mechanisms of action, such as its non-allosteric influence on GABAA receptors (Singh
& Su, 2013). Progesterone has also been shown to negatively modulate α4β2 receptors
(Bertrand, Valera, Bertrand, Ballivet, & Rungger, 1991; Lynch & Sofuoglu, 2010).
Conversely, there is evidence that the high levels of estrogen during the follicular phase
of the menstrual cycle correlate with a more highly active reward circuitry in women (Dreher,
Schmidt, Kohn, Furman, Rubinow, & Berman, 2007). This estrogenic effect may confound
efforts for successful cessation attempts, whereas the role of progesterone in the negative
signaling of the nicotinic receptor (i.e., α4β2 receptors) may assist in these attempts.
This theoretical background supports the relationship between estrogen, progesterone,
and smoking cessation-related factors. In a randomized smoking cessation trial, Allen, Bade,
Center, Finstad, and Hatsukami (2008) assigned 202 nicotine dependent women to begin
psychotherapeutic smoking cessation treatment (30 minutes of behavioral counseling and self5	
  

help manuals) in either the luteal or follicular phases of the menstrual cycle. Women who were
randomized to quit during the luteal phase of their cycle (when progesterone levels were at their
peak) demonstrated a longer period of time until relapse in comparison with those randomized to
quit during the follicular phase (where estrogen levels are elevated). Additionally after 30 days,
86% of smokers who quit during the follicular phase relapsed compared to 66% of smokers who
quit during the luteal phase (Allen et al., 2008). Furthermore, Sofuoglu and colleagues (2001)
reported that administering progesterone during the follicular phase of the cycle decreased
smoking behavior.
There is also evidence that selecting a smoking quit date during the luteal phase may
yield better cessation outcomes. Allen, Allen, Lunos, and Hatsukami (2009) found that women
(n = 138 female smokers) were more likely to relapse during the same menstrual phase in which
they quit (i.e., if a participant quit during the luteal phase, she was also more likely to relapse
during the luteal phase). The researchers attributed this to the fact that study participants
relapsed quickly. However, 51% of those who self-selected a follicular phase quit date relapsed
compared to 35% of women who self-selected a luteal phase date (Allen, Allen, Lunos, &
Hatsukami, 2009). In another study, women who were given bupropion sustained release tablets
and who self-selected quit dates in the luteal phase were more likely to have been nicotine
abstinent at a 3-month follow-up compared to those who chose a follicular phase quit date
(Mazure, Toll, McKee, Wu, & O’Malley, 2011). However, two weeks after the initial quit date,
absence was higher in the follicular phase group than the luteal phase group; 32% compared to
19%, respectively (Carpenter, Saladin, Leinbach, LaRowe, & Upadhyaya, 2008). Additional
research has reported better treatment outcomes for female smokers who schedule a quit attempt
during the follicular phase compared to the luteal phase (Franklin et al., 2008).
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Menstrual cycle and nicotine withdrawal. Together, these data provide further support
for the contention that the follicular phase in and of itself may not be related to poorer cessation
outcomes, but may be related to increases in relapse vulnerability factors that increase likelihood
for relapse. In support of this hypothesis, Carpenter and colleagues (2008) collected pilot data to
investigate the variability in cigarette craving and nicotine withdrawal across the menstrual cycle.
The study randomized female smokers to quit in either the follicular or luteal phase, and over the
course of the 6-week study the participants received two sessions (totaling 90 minutes) of
smoking cessation counseling and the transdermal nicotine patch. Women in the follicular group
reported greater withdrawal, craving, fatigue, and confusion when compared to the luteal group.
Franklin and Allen (2009) recently collaborated to develop a potential hypothesis about
the role of withdrawal in cessation attempts in the follicular phase to attempt to explain the
discordant results in research concerning menstrual cycle phase during smoking cessation
attempts. The authors cited findings that quit attempts made during both the follicular phase and
also the luteal phase have better cessation rates when compared to the opposite phase (Franklin
et al., 2008; Allen et al., 2008). Franklin and colleagues (2008) demonstrated better outcomes in
the follicular phase including both NRT, as well as a behavioral intervention. However the study
by Allen and colleagues (2008) included only a behavioral component. Thus the authors propose
that the inclusion of a pharmacotherapy may at least partially explain the varying results.
Franklin and Allen (2009) suggested that the inclusion of NRT may protect against initial
withdrawal symptoms in the follicular phase and therefore prevent increased reward.
Additionally, subjective appraisal views of past withdrawal symptoms have been
hypothesized to be a powerful influence on motivation to quit, as well as one’s efforts to make
future quit attempts (Weinberger, Maciejewski, McKee, Reutenauer, & Mazure, 2009). It has
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been suggested that smokers who recall long and severe withdrawal symptoms may be less
motivated and thus less likely to attempt cessation (Weinberger et al., 2009). Previous research
has established that more severe withdrawal symptoms occur in the late follicular phase
(Franklin & Allen, 2009; Weinberger et al., 2009). Anecdotal evidence suggests that female
smokers experience higher levels of withdrawal symptoms than male smokers and that these
symptoms may fluctuate as a function of hormone level changes across the menstrual cycle
(Carpenter et al., 2006; Perkins, 2001).
Menstrual cycle and craving. There is also evidence that the hormone fluctuations of
the female menstrual cycle augment nicotine cravings and thus it is important to consider how
this may potentially impact an individual’s ability to resist a smoking lapse (Carpenter et al.,
2006; Perkins, 2001). Sofuoglu, Babb & Hatsukami (2001) observed that administering 200mg
of progesterone during the follicular phase attenuated nicotine subjective cravings more so than a
placebo treatment. Additional research has also shown that women who quit during the
follicular phase of the menstrual cycle show a trend toward greater subjective nicotine cravings
than those who quit during the late luteal phase (Carpenter et al., 2006).
As mentioned above, a pilot study by Carpenter and colleagues (2008) randomized
female participants to quit either in the follicular or luteal phases of the menstrual cycle. The
participants received two sessions of smoking cessation counseling (totaling 90 minutes) and the
transdermal nicotine patch. Women who quit during the follicular phase reported greater levels
of subjective craving than their luteal phase counterparts. Additional research found that women
using the transdermal nicotine patch during short-term smoking abstinence (5 days of abstinence)
experienced greater reduced nicotine cravings during the luteal phase of the menstrual cycle
compared to those in the follicular phase (Allen, Hatsukami, Christianson, & Brown, 2000).
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This evidence suggests that nicotine cravings may be augmented during the follicular phase, thus
increasing the smoking lapses.
Yet some evidence suggests craving may be higher in the luteal phase. During a 3-day
period of abstinence, higher levels of subjective craving were reported during the luteal phase
(Pomerleau et al., 2000). Higher levels of cue-induced craving were observed in female smokers
during the luteal phase (Franklin, Napier, Ehrman, Gariti, O’Brien & Childress, 2004). Also,
after a 24-hour period of smoking abstinence, females in the luteal phase showed a higher
amount of craving than those in the follicular phase (Snively, Ahijevych, Bernhard, & Wewers,
2000).
Despite evidence of phase effects on craving, several studies have also observed no phase
effects on tobacco craving (Allen, Hatsukami, Christianson, & Nelson, 1999; Perkins et al.,
2000; Pomerleau, Mehringer, Marks, Downey, & Pomerleau, 2000). No phase effects were
observed in the desire to smoke among women who were tobacco abstinent (Perkins et al., 2000).
Additionally, stable craving ratings were observed across the menstrual cycle for women who
were both nicotine abstinence and smoking ad lib (Allen et al., 1999). Further, during an ad lib
smoking period, females with and without depression showed no phase differences in ratings of
nicotine craving (Pomerleau et al., 2000). It should be noted that these discordant results may be
the effect of methodological variations, small sample sizes, and inconsistent categorization of
menstrual cycle phases (cf. Carpenter et al., 2006).
Menstrual cycle and self-efficacy to quit smoking. Self-efficacy is defined as one’s
belief that he or she can successfully accomplish the goals that one sets for his or herself
(Bandura, 1977). The importance of this concept within the context of substance use behaviors
is demonstrated in Marlatt’s relapse prevention theory (Marlatt & Gordon, 1985). The theory
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details that increases in self-efficacy predict positive cessation outcomes. Thus, those
individuals with greater self-efficacy to quit are predicted to have a more successful cessation
attempt.
In congruence with this theory, it has been established that self-efficacy to quit may
predict smoking cessation treatment response. Schnoll and colleagues (2011) found that
participants with greater self-efficacy to quit smoking were more likely to be abstinent
throughout the course of treatment, as well as at a 6-month follow-up (Schnoll et al., 2011).
Further, female smokers are less confident in their ability to successfully quit smoking compared
to their male counterparts. This lower self-efficacy may make them vulnerable to more failed
quit attempts (Blake et al., 1989).
Additionally, subjective appraisal views of past withdrawal symptoms have been
hypothesized to be a powerful influence on self-efficacy to quit (Weinberger et al., 2009). Given
that more severe withdrawal symptoms occur in the late follicular phase, this may greatly
influence a female smokers’ self-efficacy in future cessation attempts (Franklin & Allen, 2009;
Weinberger et al., 2009). In fact, females making quit attempts in the follicular phase of the
menstrual cycle have reported lower levels of self-efficacy to quit compared to the luteal phase
(Carpenter et al., 2008). Thus, the follicular phase may be characterized not only by greater
nicotine withdrawal, but consequently, less self-efficacy to quit and thus, less motivation to quit.
Summary
	
  
Although there are many promising smoking cessation treatments (including
psychotherapy techniques and NRT), rates of lapse and relapse remain very high (Fiore et al.,
2000; Perkins, 2001). Female smokers have poorer cessation outcomes than males despite no
difference in motivation to quit smoking (Perkins, 2001; USDHHS, 2001). The ovarian
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hormones, progesterone and estrogen, may contribute to the gender differences in cessation
attempts; research has provided evidence that progesterone’s neuroprotective component may
contribute to successful cessation by protecting against relapse (Lynch & Sofuoglu, 2010).
However, much of current research to date does not explicitly define the follicular phase in either
number of days after the beginning of the cycle or by levels of hormones, such as estrogen. Thus,
it is unclear as to whether or not previous studies included current menses, indicating low levels
of progesterone and estrogen, within the follicular phase. This potentially confounds
interpretation of prior studies’ results.
Specific Aim 1
	
  
The primary aim of this study was to evaluate if severity of withdrawal, self-efficacy to
quit, and tobacco craving, fluctuate with phases of the menstrual cycle (i.e., luteal vs. late
follicular phases), thus potentially impacting motivation to quit.
Hypotheses 1-3. The following hypotheses were made: (1) withdrawal severity would
be higher in the late follicular phase of the menstrual cycle compared to the luteal phase; (2) selfefficacy to quit would be higher in the luteal phase compared to the late follicular phase; and (3)
greater nicotine cravings would be observed in the late follicular phase compared to the luteal
phase.
Specific Aim 2
	
  
The second aim of this study was to evaluate if the fluctuations of the menstrual cycle
affect the level of motivation for smoking cessation. There is evidence that women who selfselect a quit date in the luteal phase of the menstrual cycle experience higher rates of point
prevalence abstinence (Mazure et al., 2011). It may be that motivation to quit smoking is greater
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during the luteal phase, when withdrawal symptoms and urge to smoke are lower (Franklin &
Allen, 2009; Sofuoglu et al., 2001).
Hypotheses 4-5. It was hypothesized that participants in the luteal phase would have
higher levels of motivation to quit smoking than their counterparts in the late follicular phase.
Additionally, it was hypothesized that smoking cessation variables (i.e., withdrawal severity,
craving, and self-efficacy to quit) would moderate the relationship between menstrual cycle
phase and the motivation to quit smoking.

12	
  

METHOD AND MATERIALS
Participants
	
  
Participants included both undergraduate students and members of the Baton Rouge
community who were recruited through on-line advertisements (e.g., Craigslist, laboratory and
university-affiliated clinic websites), fliers posted on and around the campus of Louisiana State
University (LSU), and through the LSU Psychology Department undergraduate research
participant pool. All advertisement materials were tailored to recruit nicotine-dependent women
interested in quitting smoking.
A total of 86 participants completed the online survey measures. Of those participants, 9
individuals met inclusion criteria (luteal phase, n = 5; late follicular phase, n = 4; other
menstrual phases [i.e., peroviulatory or early follicular phases] were excluded, n = 6). If the
participant was not between the ages of 18-40 years old (n = 3), was male (n = 1), or did not
experience regular menses that occur every 25-35 days (n = 2; Bakos, Lundkvist, Wide, &
Bergh, 1994), they were excluded from the current study. Based upon the previous research for
smoking cessation treatment (e.g.,	
  Zvolensky, Farris, Schmidt, & Smits, 2014; Zvolensky, Baker,
Leen-Feldner, Bonn-Miller, Feldner & Brown, 2004), participants were required to smoke at
least 8 cigarettes per day for at least the past year. Participants who did not smoke daily (n = 11)
or did not smoke at least 8 cigarettes per day for at least the past year (n = 14) were excluded.
Participants also had to endorse a motivation to quit smoking of at least 5 (“I often think about
quitting smoking, but I have no plans to quit.”), but below a 9 (“I have quit smoking, but I still
worry about slipping back, so I need to keep working on living smoke free.”) on a question to
assess the participants’ current motivation to quit smoking (Appendix A). Participants who did
13	
  

not report a motivation to quit within this range were excluded (n = 5). Participants were also
excluded if use of hormonal contraceptives that do not mimic the natural menstrual cycle was
reported (n = 32), if the individual did not finish the online surveys (n = 1), or if the individual
reported conflicting information in their menstrual cycle history and thus accurate menstrual
cycle phase categorizations could not be determined (n = 2). Additional exclusion criteria
included the inability to give informed consent, any current use of smoking cessation products or
treatment, or endorsement of symptoms of premenstrual dysphoric disorder (as measured by the
Geiselman Menstrual Cycle Interview, P.J. Geiselman, personal communication, May 16, 2013),
current lactation, pregnancy in the previous six months, plans to become pregnant within the next
six months, and irregular menses that do not occur every 25-35 days were reported.
Of those participants in the late follicular phase and luteal phase at the time of completing
the survey, the average age was 26.78 (SD = 5.91, range 22-39). Participants identified as 100%
non-Hispanic White. Participants identified as 22.2% completing high school and 77.8%
completing some college. Despite a large portion of participants completing some college, only
one participant reported being a current LSU student. Approximately 22% of participants
reported being single, 44.4% reported being in a relationship, and 33.3% identified as divorced.
Participants reported an average of 15.22 cigarettes per day (SD = 4.09, range from 10-20) and
an average of 9.67 years smoking (SD = 7.97, range from 2-25). Approximately 22% of
participants reported smoking menthol brand cigarettes. Participants reported an average of 7.97
(SD = 7.23, range from 1-20) pack years. The average FTND score was 4.11 (SD = 1.45, range
from 2-7), indicating a low to moderate level of dependence. Participants reported an average of
4.00 (SD = 6.23, range from 1-20) hours since the last cigarette smoked. The majority of
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participants reported at least one past quit attempt (77.8%) and the mean number of quit attempts
was 3.33 (SD = 2.96, range from 0-10).
Measures and Materials
	
  
Independent variable
	
  
Menstrual cycle phase categorization. The Geiselman Menstrual Cycle Interview (P.J.
Geiselman, personal communication, May 16, 2013) assessed participants’ menstrual cycle
characteristics, both recently and over the history of their cycle. Characteristics assessed
include: typical length of menses, average length of cycle, and date of onset of most recent
menses. Information was utilized to determine the participants’ current phase of the menstrual
cycle.
Dependent variables
	
  
Nicotine withdrawal severity. The Minnesota Nicotine Withdrawal Scale- Revised SelfReport Measure (MNWS-R; Hughes & Hatsukami, 1986; Minnesota Nicotine Withdrawal
Scale-Revised, 2007) is a 15-item questionnaire that utilizes a Likert-type scale from zero to four
to assess the severity of the discomfort (such as irritability, depressed mood, and increased
appetite) from nicotine withdrawal. The first nine items on the self-report measure are wellvalidated and when added together, calculate the total withdrawal discomfort score (Cappelleri,
Bushmakin, Baker, Merikle, Olufade, & Gilbert, 2005). These nine items were used to calculate
the total withdrawal discomfort score for the present study and they achieve an excellent internal
consistency (α = 0.93) in the current study.
Self-efficacy to quit. The Smoking Self-Efficacy Questionnaire (SEQ-12; Etter,
Bergman, Humair, & Perneger, 2000) measures participants’ confidence to abstain from smoking
when the individual encounters various internal and external stimuli. The questionnaire contains
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two, 6-item subscales. The first subscale measures the participants’ ability to refrain from
smoking when facing internal stimuli and the second determines the ability when encountering
external stimuli (Etter et al., 2000). Internal consistency coefficients (“internal stimuli": α =
0.95; "external stimuli": α = 0.94) and test–retest intraclass correlation coefficients (0.95 and
0.93 for the two scales, respectively) are high within this measure (Etter et al., 2000). The
present study observed an excellent internal consistency, α = 0.97 for the SEQ-12 and similarly
excellent internal consistency (α = 0.95 and 0.96) was achieved for its internal and external
subscales, respectively.
Tobacco craving. The Tobacco Craving Questionnaire- Short form (TCQ-SF;
Heishman, Singleton, & Pickworth, 2008) is a shorted version of the 47-item Tobacco Craving
Questionnaire (TCQ; Heishman, Singleton, & Moolchan, 2003). The TCQ-SF draws 3 items
from each of the 4 factors of the original TCQ (emotionality, expectancy, compulsivity, and
purposefulness). The revised questionnaire takes approximately four minutes to complete, and
studies suggest that it has the same reliability and validity as the original measure (Heishman et
al., 2008; Berlin, Singleton, Heishman, 2010). In the current sample, the measure had a good
level of internal consistency, α = 0.89. The emotionality, expectancy, and compulsivity
subscales of the TCQ-SF, also achieved good levels of internal consistency in the current sample
(α = 0.83, α = 0.73, and α = 0.82, respectively). This is comparable to levels of internal
consistency in a previous study (α = 0.82, α = 0.70, and α = 0.75, respectively; Heishman et al.,
2008). The subscale of purposefulness achieved a low level of internal consistency in the current
sample (α = 0.46), which was comparable to that observed in a previous study with a larger
sample size (α = 0.48; Heishman et al., 2008).
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Motivation to quit. The Motivation to quit question (Zvolensky et al., 2014; Zvolensky
et al., 2004) was included as part of the sample descriptive questionnaire (described below). The
question asked participants to choose one of 10 statements that most accurately described the
participants’ current thoughts regarding cessation. Choices ranged from 1 (“I enjoy smoking and
have decided not to quit smoking for my lifetime.”) to 10 (“I have quit smoking and I will never
smoke again.”). Because we were interested in examining the impact of menstrual phase on
cessation-related factors among smokers interested in quitting smoking, participants were
included in the current study if they endorsed a motivation to quit smoking of at least 5 (“I often
think about quitting smoking, but I have no plans to quit.”), but below a 9 (“I have quit smoking,
but I still worry about slipping back, so I need to keep working on living smoke free.”).
Sample descriptives. A questionnaire was designed to accommodate the specific
inclusion and exclusion criteria for this study (based upon Vinci, Peltier, Shah, Kinsaul, Waldo,
McVay, & Copeland, 2014). The measure consisted of 10 items that assessed age, gender, race
and ethnicity, relationship status, level of education, current hormonal contraceptives and
medications used, pregnancy and lactation status, daily smoking rate, years smoked, preferred
brand of cigarettes, and previous quit attempts. Fagerström Test for Nicotine Dependence
(FTND; Heatherton, Kozlowski, Frecker, & Fagerström, 1991) is a six-item questionnaire
assessing for nicotine dependence. It evaluates the quantity of cigarette consumption, frequency
of use, and craving to smoke. Possible scores range from 0-10, with a higher score suggesting
greater dependence. FTND scores correlate with physiological measurements, such as cotinine
and number of years smoked (Etter, Duc, & Perneger, 1999; Heatheron et al., 1991; Pomerleau,
Carton, Lutzke, Flessland, & Pomerleau, 1994). Higher scores on the measure also correspond
with more expected withdrawal symptoms and lower self-efficacy to quit (Dijkstra & Tromp,
17	
  

2002; Etter, 2005; Etter, Ussher, & Hughes, 2013; Pomerleau et al., 1994). In the current study,
the measure achieved lower internal consistency (α = 0.33) than previously observed (e.g., α =
0.61; Heatherton et al., 1991).
Procedure
	
  
The study was approved by the university’s Institutional Review Board prior to data
collection. Interested participants provided informed consent and completed a series of measures
via online survey using surveymonkey.com. If a prospective participant contacted the laboratory
via email or telephone, she was provided the link to the online survey and invited to participate
in the study.
Upon survey completion, all participants were thanked for their participation and
received information on smoking cessation treatment at the Louisiana State University
Psychological Services Center. Participants enrolled through the student participant pool
received research credit for participating in the study and those enrolled via the community were
entered into a lottery-style prize drawing ($50).
Data Analytic Strategy
	
  
Based upon prior research finding a large effect of menstrual cycle phase on smokingrelated outcomes (Carpenter et al., 2008), a total of 52 participants (26 in each group) was the
target goal to obtain an estimated large effect size (Cohen’s f = 0.40) with a power of .80 and
alpha level of .05 (calculated with G*power; Faul, Erdfelder, Lang, & Buchner, 2007; based on
Carpenter, et al., 2008). However, in congruence with previous research which recruited
participants based upon cycle phase in a clinical setting, under similar time constraints (McVay,
2012), it was not possible to recruit and retain the total number of participants that were
predicted to establish a significant effect. All foreseeable recruitment efforts were made to
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achieve the proposed sample size; however since the needed 52 participants could not be
recruited and retained through the study procedures, effect sizes and confidence intervals for all
groups were also calculated.
To test for any between group differences (luteal vs. late follicular) on descriptive
variables, one-way analyses of variance (ANOVAs) between the two groups were conducted for
each of the continuous variables, including: age, daily smoking rate, number of years smoked,
number of pack-years, severity of nicotine dependence, and number of previous quit attempts.
Additionally, chi-square analyses were conducted to test for any between group differences in
the categorical descriptive variables, including: race/ethnicity, education level, and referral
status (psychology subject pool vs. community). Effect sizes for all ANOVA analyses were
determined using d (continuous variables) and Crammer’s V (categorical variables; Cohen, 1988;
Acock & Gordon, 1979). Effect sizes for d are considered as small (d = 0.20), medium (d =
0.50), and large (d = 0.80; per Cohen, 1992). Additionally, effect sizes for Crammer’s V are
considered as small (V = 0.10), medium (V = 0.30), and large (V = 0.50; per Cohen, 1992).
To investigate whether the menstrual cycle phase affected the variables of withdrawal
severity, self-efficacy to quit, tobacco craving, and motivation for smoking cessation, a series of
one-way, between-subjects ANOVAs were conducted comparing menstrual cycle phase (luteal
or late follicular phase) on the these variables.
Finally, to determine if smoking-related variables (i.e., withdrawal severity, craving, and
self-efficacy to quit) moderated the relationship between menstrual cycle phase and the
motivation to quit smoking, moderation analyses were conducted using hierarchical linear
regression as per guidelines set by Baron and Kenny (1986). Predictors were centered to address
multicollinearity. Separate models were conducted for each moderator. In Step 1, the main
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effects of the menstrual cycle phase (luteal phase and late follicular phase) and one of the
proposed moderators (i.e., withdrawal severity, craving, self-efficacy to quit) were entered. The
interaction between menstrual cycle and the smoking-related variable were entered in Step 2 of
each model. Effect sizes were determined using f2 (Cohen, 1988) and defined as small (f2 =
0.02), medium (f2 = 0.15), and large (f2 = 0.35; Cohen, 1992).
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RESULTS

	
  
Demographics
	
  
See Table 1 for sample descriptives by phase group. The groups did not significantly
differ in age, number of cigarettes per day, or number of years smoking. Additionally, there
were no differences between groups in number of pack years, FTND score, number of hours
since last cigarette smoked, or number of quit attempts. Despite no significant differences
between groups in demographic variables, there was a medium effect of the number of hours
since last cigarette smoked, with a longer amount of abstinence observed in the luteal phase.
Additionally, there was a large effect of the number of quit attempts, with a larger number of
past quit attempts reported by participants in the luteal phase.
Chi-square analyses were conducted to assess differences between groups on the
categorical variables of education level, relationship status, past quit attempts, and menthol
cigarette brand. Results revealed no significant differences between groups on education level,
relationship status, past quit attempts, or menthol cigarette brand. All effect sizes were small.
Nicotine withdrawal severity1
See Table 2 for means, standard deviations, confidence intervals, and ANOVA results.
There were no differences between groups regarding withdrawal severity; the effect size was
very small.

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
1
	
  Analyses of covariance (ANCOVA) were conducted to control for length of time since last
cigarette smoked and number of quit attempts. These analyses yielded non-significant
differences between groups on smoking cessation-related variables and very small effect sizes.
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Table 1.
Differences between menstrual cycle phase groups demographic variables
Menstrual Cycle Phase
Group
Dependent Variable

Luteal Phase

Mean Age (SD)
27.40 (6.69)
Cigarettes per day
15.40 (4.56)
Years smoked
10.60 (8.56)
FTND score
4.20 (1.92)
Pack years
9.35 (6.89)
Hours since last cigarette
5.80 (8.23)
Number of quit attempts
4.60 (3.29)
Education
55.56
(% some college)
Relationship status
22.22
(% in relationship)
Made quit attempt (%)
55.56
Menthol cigarette (%)
22.22
Note. CI = Confidence Interval

Late
Follicular
Phase

Luteal Phase
95% CI

Late
Follicular
Phase 95% CI

F or
χ2

df

p

26.00 (5.66)
15.00 (4.08)
8.50 (8.27)
4.00 (0.82)
7.50 (8.69)
1.75 (0.96)
1.75 (0.85)
22.22

[19.09, 35.71]
[9.74, 21.06]
[-0.03, 21.23]
[1.82, 6.59]
[-0.21, 16.91]
[-4.42, 16.02]
[0.52, 8.68]
-

[17.00, 35.00]
[8.50, 21.50]
[-4.65, 21.65]
[2.70, 5.30]
[-6.33, 21.33]
[0.23, 3.27]
[-0.97, 4.47]
-

0.11
0.02
0.14
0.37
0.27
0.93
2.43
3.21

1, 8
1, 8
1, 8
1, 8
1, 8
1, 8
1, 8
1

0.75
0.90
0.72
0.85
0.87
0.37
0.16
0.07

d
or
Cramer’s
V
0.48
0.09
0.25
0.14
0.11
0.69
1.09
0.15

22.22

-

-

2.25

1

0.33

0.13

22.22
11.11

-

-

3.21
0.23

1
1

0.73
0.64

0.15
0.16
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Tobacco craving1
See Table 2 for means, standard deviations, confidence intervals, and ANOVA results.
There were no significant differences regarding tobacco craving, and there was a small effect
size. There were also no phase group differences on the following subscales of the TCQ-SF:
emotionality, compulsivity, and purposefulness. There was a large effect of menstrual cycle
phase on the expectancy subscale of the TCQ-SF, such that the luteal phase group was greater
than the late follicular phase group.
Self-efficacy to quit1
See Table 2 for means, standard deviations, confidence intervals, and ANOVA results.
There were no differences between groups regarding self-efficacy to quit; there was a very small
effect size. No group differences and small effect sizes were revealed on the internal and
external subscales of the SEQ-12, F(1,7) = 0.85, p = 0.78, d = 0.19, and F(1,7) = 0.01, p = 0.93,
d = 0.06, respectively.
Motivation1
See Table 2 for means, standard deviations, confidence intervals and ANOVA results.
There were no differences between phase groups on motivation to quit smoking.
Moderation analyses
	
  
See Table 3 for results of multiple linear regression analyses. Effect sizes for hierarchical
multiple regression analyses were small and did not support any proposed moderators between
participant menstrual cycle phase and motivation to quit smoking. After 2.2% variance was
accounted for by the main effects of nicotine withdrawal and menstrual cycle phase group, the
interaction of nicotine withdrawal and phase group accounted for 0.30% of the variance in the
model. Additionally, after 34.7% variance was accounted for by the main effects of tobacco
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Table 2.
Differences between menstrual cycle phase groups and smoking cessation-related variables
Menstrual Cycle Phase Group
Dependent Variable

Luteal Phase

Mean MNWS-R (SD)
15.60 (8.50)
TCQ-SF
67.20 (16.07)
TCQ-SF: emotionality
15.00 (5.10)
TCQ-SF: expectancy
19.40 (2.30)
TCQ-SF: compulsivity
15.40 (6.19)
TCQ-SF: purposefulness 17.40 (4.78)
SEQ
37.00 (19.17)
SEQ: internal
19.40 (9.04)
SEQ: external
17.60 (10.36)
Motivation
6.80 (1.01)
Note. CI = Confidence Interval

Late
Follicular
Phase
16.00 (16.33)
61.50 (16.82)
14.25 (7.27)
16.00 (4.69)
13.75 (5.32)
17.50 (2.65)
34.75 (22.94)
17.50 (10.60)
18.25 (12.42)
7.00 (0.82)

Luteal Phase
95% CI
[5.04, 26.16]
[47.23, 87.15]
[8.67, 21.33]
[16.54, 22.26]
[7.72, 23.08]
[11.47, 23.33]
[13.20, 60.80]
[8.17, 30.63]
[4.74, 30.46]
[5.44, 8.16]
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Late
Follicular
Phase 95% CI
[-9.98, 41.99]
[34.73, 88.27]
[2.68, 25.83]
[8.54, 23.46]
[5.29, 22.21]
[13.29, 21.71]
[-0.75, 72.25]
[0.64, 34.37]
[-1.51, 38.01]
[5.70, 8.30]

F

df

p

d

0.002
0.27
0.03
2.06
0.18
0.02
0.01
0.85
0.01
0.09

1,7
1,7
1,7
1.7
1,7
1,7
1,7
1,7
1,7
1,7

0.96
0.62
0.86
0.19
0.69
0.97
0.93
0.78
0.93
0.77

0.03
0.35
0.12
0.92
0.28
0.03
0.06
0.19
0.06
0.21

craving and menstrual cycle phase group, the interaction of tobacco craving and menstrual cycle
phase group accounted for 1.0% of the variance in the model. In regards to motivation to quit
moderating self-efficacy to quit and participant menstrual cycle phase, after 6.2% variance was
accounted for by the main effects of self-efficacy to quit and menstrual cycle phase group, the
interaction of self-efficacy to quit and phase group accounted for 2.0% of the variance in the
model.
Table 3.
Hierarchical linear regression of potential moderators of menstrual cycle phase and
Motivation to quit smoking
ΔR2

ΔF

Β

t

p

sr2

f2

Nicotine Withdrawal Severity
Step 1

0.02

0.07

Menstrual cycle phase group
Nicotine withdrawal severity
Step 2

0.003

0.94
-0.12 -0.29

0.79

0.01

-0.01 -0.24

0.82

0.01

0.02

Menstrual cycle phase group X
Nicotine withdrawal severity

0.02

0.90
-0.18 -0.38

0.72

0.00
0.01

Tobacco Craving
Step 1

0.35

1.60

Menstrual cycle phase group
Tobacco Craving
Step 2

0.01

0.28
0.00 -0.00

0.99

0.00

-0.59 -1.75

0.16

0.33

0.07

Menstrual cycle phase group X
Tobacco craving

0.71
0.14
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1.16

0.26

0.80

0.03
0.01

Table 3 (cont.).
Self-Efficacy to Quit
Step 1

0.06

0.20

Menstrual cycle phase group

-0.12 -0.31

Self-efficacy to quit
Step 2

0.83

0.22
0.02

Menstrual cycle phase group X
Self-efficacy to quit

0.21

0.77

0.02

0.60

0.05

0.75
0.20
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0.56

0.57

0.34

0.75

0.19
0.02

	
  

DISCUSSION
The present study examined the effects of the female hormonal milieu, specifically the

effect of menstrual phase (luteal vs. late follicular) on smoking cessation-related variables (i.e.,
nicotine withdrawal, tobacco craving, level of self-efficacy to quit, and motivation), which can
affect an individual’s cessation attempt. However, this study showed only small effect sizes and
no significant differences between participants in the luteal and late follicular phases in regards
to levels of nicotine withdrawal severity, tobacco craving, or self-efficacy to quit, as well as the
level of motivation between participants in the luteal and late follicular phase. Additionally,
there was no evidence that the smoking cessation-related variables moderated the relationship
between phase group and motivation to quit.
There were no significant group differences between the phase groups (luteal vs. late
follicular) in demographic variables; however, there was a medium effect of length of time since
last cigarette (measured in hours), with the luteal phase group reporting longer periods of
abstinence. Previous literature has suggested that the luteal phase may have therapeutic utility in
smoking cessation, due to its high levels of the neuroprotective hormone, progesterone (Lynch &
Sofuoglu, 2010). It has been shown that females making a quit attempt during the luteal phase
report lower levels of nicotine withdrawal and craving (Carpenter et al., 2008), thus making it
easier to abstain from smoking for a longer period of time. In the present study, a longer period
of abstinence was observed in the luteal phase, as expected; however, there were no significant
differences and only small effect sizes between groups in withdrawal and craving severities.
Because of the lack of differences or compelling effect sizes observed in the present study
between phase groups in regards to withdrawal and craving ratings, the medium effect of the
amount of time since last cigarette could be explained by one participant in the luteal phase
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group who abstained from smoking for 20 hours. Others participants in the luteal phase
abstained from smoking for an average of 2.50 (SD = 2.25) hours, which was similar to the late
follicular phase group of 1.75 (SD = 0.96) hours. The average time participants abstained from
smoking in the current study is consistent with previous literature, which identified female
participants as smoking over 18 cigarettes per day (Carpenter et al., 2008), which when smoked
over the course of a day yields a similar time of abstinence between cigarettes as observed in the
luteal and late follicular groups of the present study.
Withdrawal severity was non-significantly lower during the luteal phase, in comparison
to the late follicular phase and this was a very small effect. These results replicate previous
research that shows no significant differences in nicotine withdrawal symptomatology between
the luteal and follicular phases of the menstrual cycle (Allen et al., 1999; Snively et al., 2000).
Allen and colleagues (1999) reported that nicotine withdrawal symptomatology remains stable
throughout the menstrual cycle and no differences were observed between the follicular and late
luteal phases in terms of smoking behavior and smoking cessation-related variables (i.e., nicotine
withdrawal). However, recent pilot data suggest that females in the follicular phase report
greater withdrawal, craving, fatigue, and confusion when compared to the luteal group during a
quit attempt (Carpenter et al., 2008). The present study recruited a smaller sample size (luteal
phase, n = 5; late follicular phase, n = 4) than Carpenter and colleagues’ (2008) pilot data set
(follicular phase, n = 25; luteal phase, n = 19). Additionally, the pilot data did not distinguish
between the early vs. late follicular menstrual cycle phases. The early follicular phase is
typically characterized by the onset of menses, where both estrogen and progesterone levels are
low until the beginning of the late follicular phase (Davidens et al., 2007). Estrogen levels begin
to elevate during the late follicular phase, while progesterone levels remain low (Davidsen et al.,
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2007). Thus, combining the early and late follicular phases into one phase category potentially
obscures any cessation-related effects, which may be related to the fluctuation of hormone levels
across the menstrual cycle. Thus, not distinguishing between the early and late follicular phases
potentially masks observable differences in craving, withdrawal, self-efficacy, and motivation
between the two follicular phase categories. Additional research is needed to clarify if quitting
during the luteal phase of the menstrual cycle as opposed to the late follicular phase significantly
affects a premenopausal female’s quit attempt (especially withdrawal severity). Research also
needs to further investigate the differences in smoking cessation-related variables between the
early vs. late follicular phases of the menstrual cycle.
Although levels of tobacco craving were slightly higher during the luteal phase, the effect
of phase on craving was small and not significant. This is consistent with previous research
(Perkins et al., 2000) that found no differences between phase groups on craving. However,
despite research establishing that there is no overall phase effect on craving, when using the
transdermal nicotine path, women in the late luteal phase have shown lower craving ratings
(Allen et al., 1999). Franklin & Allen (2009) theorize that the inclusion of a pharmacotherapy
during a quit attempt may impact subjective craving ratings during the luteal phase. Thus the
impact of the menstrual cycle phase on inclusion of pharmacotherapy (i.e., nicotine replacement
therapy) in a quit attempt needs to be further clarified through future research. Although many
studies to date have investigated the fluctuations of craving across the menstrual cycle (cf.
Carpenter et al., 2006), the present study is the first to utilize the TCQ-SF and thus the first to
look at components of tobacco craving (i.e., emotionality, expectancy, compulsivity, and
purposefulness). The inclusion of these subscales is important, as they illustrate the complex
processes that underlie craving in smoking behavior (Heishman et al., 2008). In the present
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study, the subscales of the emotionality, compulsivity, and purposefulness demonstrated only
non-significant differences and small effect sizes between groups.
Notably, there was a non-significant, but large effect of phase on the TCQ-SF subscale
for tobacco expectancy, with the luteal phase group reporting higher expectancies. This subscale
asks participants to rate items such as how much one would enjoy a cigarette right now or how
“good” a cigarette would taste in the current moment. Thus, the scale evaluates anticipated
positive effect of smoking a cigarette (Heishman et al., 2008). High levels of estrogen, as
observed during the follicular phase of the menstrual cycle, correlate with a more highly active
reward circuitry (Davidsen et al., 2007) and this reward circuitry is associated with encoding and
evaluating expectancy of rewards, including drug rewards (Gardner, 2011). Recent research
established that smokers have less menstrual phase variation of estrogen across the cycle
(Dušková et al., 2012). The large effect size observed in the expectancy subscale of the TCQ-SF
may be explained in part by these more stable levels of estrogen in female smokers. Given that
the luteal phase is characterized by not only heightened levels of progesterone, but also to a
lesser extent elevated levels of estrogen (Davidsen et al., 2007), more stable levels of estrogen
may augment the activation of the reward circuitry during the luteal phase. Thus, this would
contribute to females in the luteal phase more highly evaluating the expectancy of nicotine
rewards.
There were no significant differences in levels of self-efficacy to quit smoking between
the luteal and late follicular phase groups and the size of the effect of phase on self-efficacy was
small. One study to date has explicitly explored the fluctuation of self-efficacy to quit across the
menstrual cycle. This research demonstrated decreases in self-efficacy during the follicular
phase (Carpenter et al., 2008). The present study had a smaller sample size when compared to
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Carpenter and colleagues’ (2008) pilot data and our limited sample size may account for the
present study’s lack of observable difference in self-efficacy to quit between the luteal phase and
the late follicular phase. Additional research is needed to clarify whether or not self-efficacy to
quit is stable across the menstrual cycle.
Similarly, there were not significant differences between phase groups in terms of
motivation to quit smoking. Motivation was slightly lower during the luteal phase when
compared to the late follicular phase; however this was also non-significant and a small effect
size. Weinberger and colleagues (2009) theorized that smokers who remember or experience
long and severe withdrawal symptomatology may be not only less motivated to quit, but also less
confident in his or her ability to quit. Thus, in light of the lack of significant differences in
withdrawal severity between phase groups, it is not surprising that no significant differences and
only small effect sizes were observed in motivation.
Finally, smoking cessation-related variables (i.e., withdrawal severity, craving, and selfefficacy to quit) did not moderate the relationship between menstrual cycle phase and the
motivation to quit smoking. This finding was not surprising in light of the finding that the
smoking cessation-related variables did not differ between phases and it suggests that timing
cessation attempts with the luteal phase may not dramatically improve treatment outcomes. To
date, this is the first study to investigate if smoking cessation-related variables would moderate
the relationship between menstrual cycle phase and the motivation to quit smoking. In the
present study, the effect sizes for hierarchical multiple regression analyses were small and did
not support any of the proposed moderators between participant cycle phase and motivation to
quit smoking. Additionally, the interactions between the proposed moderators (i.e., withdrawal
severity, craving, and self-efficacy to quit) and participant cycle phase did not account for a
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substantial portion of the variance in their respective models. Due to the lack of prior research
investigating the variables that potentially moderate the relationship between motivation to quit
smoking and menstrual cycle phase, as well as the fluctuations of the underlying components of
craving (i.e. emotionality, expectancy, compulsivity, and purposefulness) across the cycle,
additional research should explore if specific components of craving moderate the relationship
between motivation to quit and cycle phase.
The findings of the present study are consistent with a recent review, which detailed the
results of five research studies suggesting that female premenopausal smokers who have higher
levels of progesterone than their non-smoking counterparts, and thus higher levels of
progesterone (as seen in the luteal phase) would not significantly alter smoking behaviors (Allen
et al., 2014). This indicates that the luteal phase may not be an optimum time to make a quit
attempt (Allen et al., 2014). However, the review makes note that there have been substantial
difficulties in interpreting the literature surrounding ovarian hormones and smoking
behavior/cessation, as there is a lack of consistency in methodology and continuously fluctuating
endogenous hormone levels, among other concerns.
If future studies observe higher negative symptoms (i.e., higher tobacco craving and
nicotine withdrawal) and simultaneous higher self-efficacy to quit during one phase of the
menstrual cycle (i.e., luteal or late follicular), research should test if these variables interact to
predict motivation. If so, it may prove to be an optimum time for health care providers to
encourage female smokers to make a quit attempt. Health care providers are beginning to utilize
motivational interviewing (MI) to encourage patients to make positive behavioral changes
(Rubak, Sandbaek, Lauritzen, & Christensen, 2005). A fundamental goal of MI is to develop a
discrepancy between the client’s current behavior and his or her desired behavior, thus
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highlighting the importance of change. Developing discrepancy was originally framed as
cognitive dissonance; however, MI has since described it as the discrepancy between the
patient’s status quo and the desired change goal (Festinger, 1957; Miller & Rollnick, 2013).
Through the use of specific questions and selective reflections, change will often occur when the
patient perceives a discrepancy between problem behaviors and a broader set of values (Burke et
al., 2003). Thus, as a female smoker experiences increased negative symptoms, such as craving,
this may afford the opportunity for the client to view smoking as a problem behavior.
Timing this type of MI-based intervention with greater negative symptoms may make the
female more committed to resolve the discrepancy and thus start making behavioral changes.
Furthermore, prior research has established that MI interventions demonstrate some efficacy in
both males and females, despite lower rates of confidence to quit in female smokers (Dunn et al.,
2001; Whitlock et al., 1997). Heckman and colleagues (2010) report that patients (the majority
of whom were females), who received an MI-based treatment reported an increase of 45% in
abstinence rates at follow-up when compared to controls, indicating potential promise in utilizing
brief motivational interview (BMI) in female cessation attempts. Timing the MI-based
intervention with a patient’s menstrual cycle may improve psychosocial interventions with
female smoking cessation patients.
This area of research is significant in that tobacco smoking results in nearly 1 million
female deaths per year worldwide and is expected to increase to approximately 3 million deaths
per year by 2020 (Peto, Lopez, Boreham et al., 1996). Despite no significant gender differences
in rates of cessation attempts or motivation to stop smoking, female smokers have poorer
cessation outcomes, making the increasing rates of smoking-related deaths an area of female
health concern (USDHHS, 2001; Perkins, 2001). To increase successful female smoking
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cessation attempts, more female-specific tailored cessation treatments may be needed. This is
the first study to specifically examine whether the variables that affect cessation success
(withdrawal, craving, self-efficacy, and motivation) differ across the luteal (when progesterone
levels are at their peak) and late follicular (when estrogen levels are rising) phases of the
menstrual cycle.
Limitations and future directions
	
  
The current study should be interpreted in light of its limitations. One major limitation is
that it was underpowered. A posteriori power analysis determined that the present study
obtained a power of .06 and an alpha of .05, with the current sample size of 9 participants
(calculated with G*power; Faul et al., 2007). For the present study, a total of 43 more
participants (22 in the late follicular group and 21 in the luteal group) would be needed to obtain
an estimated large effect size (based on Cohen’s d), with a power of 0.08 and alpha level of .05
(calculated with G*power; Faul et al., 2007; based on Carpenter, et al., 2008), as determined by
the a priori analyses. Thus, more participants are needed to achieve adequate power for the
study. Additionally, this study characterized current menstrual cycle phase utilizing only
participant self-report measures. Prior research has indicated that self-reported menstrual cycle
history and calendar-based counting methods should not be used alone to categorize menstrual
cycle phase events (Wideman, Montgomery, Levine, Beynnon, & Shultz, 2013). Thus in future
research, it is suggested that ovulation testing and if possible, serum blood tests of progesterone
and estrogen levels are utilized to determine current cycle phase.
Also, the present study did not control for a specific time of smoking abstinence (i.e.,
specific number of hours since last cigarette smoked). Other research groups monitored
withdrawal and craving symptomatology within the context of a quit attempt (at least 24 hours of
34	
  

abstinence; Allen et al., 2008). In the current sample, all of the participants had smoked within
the past 24 hours, with participants ranging from 1 hour to 20 hours of smoking abstinence. A
greater amount of time in which the participants abstained from smoking, as observed in
previous studies may elevate the withdrawal and craving scores (Allen et al., 2008). This may
highlight the differences between menstrual cycle phases observed in previous studies (Allen et
al., 2008). Finally, the sample consisted of only non-Hispanic White females, which limits the
generalizability of these results across females.
Regarding strengths of the present study, this was the first study to explicitly investigate
the impact of female sex hormones in the luteal and late follicular phases of the menstrual cycle
on withdrawal, craving, self-efficacy to quit, and motivation to quit. Previous studies (i.e.,
Carpenter et al., 2008; Allen et al., 2008) do not separate the early vs. late follicular phases and
thus may confound previously established results. By not distinguishing between the early and
late follicular phases, these studies have potentially obscured any cessation-related effects
observed across the menstrual cycle. Additionally, this is the first study to date to consider the
underlying constructs of tobacco craving and investigate these components’ fluctuation across
the menstrual cycle. The present study was also the first to explore whether the smoking
cessation-related variables would moderate the relationship between menstrual cycle phase and
the motivation to quit smoking.
Although no significant differences were observed in the present study, possibly due to a
small and underpowered sample size, future research should continue to investigate the role of
menstrual cycle phase fluctuations in smoking cessation. In future research, if greater negative
symptoms such as tobacco craving and nicotine withdrawal intensity, as well as greater selfefficacy to quit are observed in the luteal phase, it may be worthwhile to conduct additional
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research to investigate whether or not a MI-based intervention for smoking cessation would be
more effective if implemented in the luteal phase of the menstrual cycle.
Conclusions
	
  
Results of the current study did not show a difference between smoking cessation-related
variables (i.e., withdrawal severity, craving intensity, and self-efficacy) and level of motivation
between participants in luteal and late follicular phases. Additionally, these variables did not
moderate the relationship between menstrual cycle phase and motivation to quit. Results should
be interpreted with caution, however, in light of a small sample size. Further research is
necessary to determine if there is a difference between smoking outcome variables and
motivation to quit over the course of the menstrual cycle. If differences are present, MI-based
interventions may be the most beneficial psychosocial interventions for female smoking
cessation patients.
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APPENDIX A
Motivation to quit question for Survey Monkey
“Please pick the statement that most accurately describes your current thoughts about
quitting.”
1)
2)
3)
4)
5)
6)
7)
8)
9)
10)

I enjoy smoking and have decided not to quit smoking for my lifetime.
I never think about quitting smoking, and I have no plans to quit.
I rarely think about quitting smoking, and I have no plans to quit.
I sometimes think about quitting smoking, but I have no plans to quit.
I often think about quitting smoking, but I have no plans to quit.
I definitely plan to quit smoking in the next 6 months.
I definitely plan to quit smoking in the next 30 days.
I still smoke, but I have begun to change, like cutting back on the number of cigarettes
I smoke per day. I am ready to set a quit date.
I have quit smoking, but I still worry about slipping back, so I need to keep working on
living smoke free.
I have quit smoking and I will never smoke again.
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APPENDIX B
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Informed Consent Form
1. Study Title: The Impact of Timing Menstrual Cycle Phase with Brief Motivational
Interviewing on Smoking Lapse
2. Performance Sites: This study will be conducted at the Louisiana State University
Psychological Services Center (PSC), 33 Johnston Hall.
3. Investigators: The Principal Investigator, Julia D. Buckner, Ph.D., can be reached at 225-5784096, Monday-Friday between 9:00 a.m. and 5:00 pm or at jbuckner@lsu.edu.
Paula Geiselman, Ph.D, and MacKenzie R. Peltier, B.A. are co-investigators.
Additional research staff can be contacted at 225-578-8626, M-Fr between 9:00
a.m. and 5:00 p.m or at lsusmokingresearch@gmail.com.
4. Purpose of the Study: The proposed study is designed to investigate the role of ovarian
hormones (i.e. progesterone and estrogen) in smoking cessation treatment, mood
states, and food cravings.
5. Study Inclusion: Female participants between the ages of 18-40 years old who experience
regular menses that occur every 25-35 days. Participants must smoke at least 8
cigarettes/day for at least the past year. Additionally, participants must endorse a
motivation to quit smoking; however, participants must not have quit yet.
Exclusion criteria will include the following: inability to give informed consent,
current use of smoking cessation products or treatment, use of hormonal
contraceptives that do not mimic the natural menstrual cycle, symptoms of
premenstrual dysphoric disorder (as measured by the Geiselman Menstrual Cycle
Interview), current lactation, pregnancy in the previous six months, plans to
become pregnant within the next six months, and irregular menses that do not
occur every 25-35 days.
6. Number of Subjects: The maximum number of participants enrolled in this study will be 100.
7. Study Procedures: The study requires that you will complete a series of self-report
assessments about your nicotine use patterns, smoking beliefs, mood states, and
food cravings.
8. Benefits:

You may derive benefit from participating in the self-assessment about your
smoking, as participation may increase your awareness of your smoking
behaviors. You may also develop a better understanding of research methodology.
In addition, you will be contributing to the knowledge regarding how ovarian
hormones may impact smoking processes and food cravings, which may help
smokers successfully, quit in the future.
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9. Risks/Discomforts: As with any study, there is a possible loss of confidentiality. You might
feel uncomfortable disclosing and discussing personal information.
10. Injury/Illness: In the unlikely event of injury or medical illness resulting from study
participation, participants are instructed to seek necessary medical care from their
physician and contact the Principal Investigator, Julia Buckner, PhD (225-5784096). The expense of medical treatment will be your responsibility. No
compensation is available in case of study-related illness or injury.
11. Right to Refuse: Participation in this study is voluntary, and you may withdraw from the
study at any time without any penalty at this present time or in the future at LSU.
Choosing to not participate or withdraw at any time from the study will not
jeopardize your academic standing at LSU or adversely affect your relationship
with LSU or the research staff. The research staff reserves the right to drop
participants from the study for the benefit and safety of the participant or research.
However, if you are an undergraduate psychology student and choose to not
participate in this screening survey, as indicated by choosing the "I do not agree to
participate at this time" option below, you will not receive SONA credit since you
are not completing the survey, but you will also not be penalized for your decision
to not participate. Instead you will be granted an excused no-show.
12. Privacy:

Results of this study may be published, but no names or identifying information
will be included in the publication. All personal information obtained in this study
will be kept confidential unless release is legally compelled. Once all data have
been collected, your name and telephone number will be destroyed. During the
study, you will be assigned an identification number, and this number will be the
only link between your name, phone number, and your responses. Your forms
will be kept in a locked filing cabinet in a locked office. Only research staff
members will have access to data files or other research-related information. The
information collected in this research study will not be linked to your academic or
judicial records at LSU.

13. Financial Information: Community participants will receive compensation via a lottery-style
cash and prize drawing ($50) for completing study session. Participants who are
recruited from the LSU Department of Psychology Undergraduate Student
Research Participation Pool will earn class credit for completion of the study
session.
All participants will be referred to the LSU PSC for smoking cessation treatment.
14. Signatures:
The study has been discussed with me and all my questions have been answered. I may
direct additional questions regarding study specifics to the investigators. If I have questions
about subjects’ rights or other concerns, I can contact Dennis Landin, Institutional Review
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Board, (225) 578-8692, irb@lsu.edu, www.lsu.edu/irb. I agree to participate in the study
described above and acknowledge the researchers’ obligation to provide me with a copy of this
consent form if signed by me.
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